Journal of Antimicrobial Chemotherapy (1999) 43, 113-118
© 1999 The British Society for Antimicrobial Chemotherapy
The clinical efficacy of continuous-infusion flucloxacillin in serious staphylococcal sepsis
a Infectious Disease and Clinical Epidemiology Department, Monash Medical Centre, 246 Clayton Road, Clayton, VIC 3168; b Department of Microbiology and Infectious Diseases, Women's and Children's Hospital, 72 King William Road, North Adelaide, SA 5006; c Department of Epidemiology and Preventive Medicine, Monash University, Clayton, Victoria, Australia
Since the efficacy of ß-lactams against pathogens such as methicillin-susceptible Staphylococcus aureus (MSSA) is related to the time for which serum drug concentrations exceed the MIC for the pathogen, administration of anti-staphylococcal ß-lactams by continuous infusion may provide a more suitable means of drug delivery than intermittent dosing. To assess the clinical efficacy of continuous-infusion therapy, we reviewed the outcomes for 20 consecutive patients with proven serious MSSA sepsis (three with endocarditis, ten osteomyelitis, one endocarditis plus osteomyelitis and six deep abscess) treated with continuous-infusion flucloxacillin (8–12 g/day). Patients initially receiving routine intermittent-dose flucloxacillin therapy were changed to continuous-infusion flucloxacillin (mean duration 29 days; range 4–60 days) for completion of their treatment course. In the majority of cases this was given at home. Serum flucloxacillin concentrations during continuous-infusion flucloxacillin 12 g/day were 11.5–>40 mg/L (ten patients) and those during continuous-infusion flucloxacillin 8 g/day were 8–>40 mg/L (five patients), these concentrations being well above the expected MIC of flucloxacillin for MSSA. Continuous-infusion flucloxacillin was well tolerated by most patients, and 14/17 patients (82%) who completed their course of continuous-infusion flucloxacillin were judged clinically and microbiologically cured at long-term follow-up (mean 67 weeks; range 4–152 weeks). These preliminary data suggest that, following initial intermittent-dose flucloxacillin therapy, continuous-infusion flucloxacillin is an effective treatment option for serious MSSA sepsis, and forms a feasible and possibly preferable alternative to glycopeptides when considering home-based parenteral therapy for these infections. Further studies are needed to identify whether continuous-infusion flucloxacillin can entirely replace intermittent-dose therapy for such infections.
* Corresponding author. Infectious Disease and Clinical Epidemiology Department, Monash Medical Centre, 246 Clayton Road, Clayton, VIC 3168, Australia. Tel: +61-3-9550-4564; Fax: +61-3-9550-4533; E-mail: Lindsay.Grayson{at}med.monash.edu.au
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. B. Landersdorfer, C. M. J. Kirkpatrick, M. Kinzig-Schippers, J. B. Bulitta, U. Holzgrabe, G. L. Drusano, and F. Sorgel Population Pharmacokinetics at Two Dose Levels and Pharmacodynamic Profiling of Flucloxacillin Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3290 - 3297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Viaene, H. Chanteux, H. Servais, M.-P. Mingeot-Leclercq, and P. M. Tulkens Comparative Stability Studies of Antipseudomonal {beta}-Lactams for Potential Administration through Portable Elastomeric Pumps (Home Therapy for Cystic Fibrosis Patients) and Motor-Operated Syringes (Intensive Care Units) Antimicrob. Agents Chemother., August 1, 2002; 46(8): 2327 - 2332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Jensen, C. H. Wachmann, F. Espersen, J. Scheibel, P. Skinhoj, and N. Frimodt-Moller Treatment and Outcome of Staphylococcus aureus Bacteremia: A Prospective Study of 278 Cases Arch Intern Med, January 14, 2002; 162(1): 25 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wysocki, F. Delatour, F. Faurisson, A. Rauss, Y. Pean, B. Misset, F. Thomas, J.-F. Timsit, T. Similowski, H. Mentec, et al. Continuous versus Intermittent Infusion of Vancomycin in Severe Staphylococcal Infections: Prospective Multicenter Randomized Study Antimicrob. Agents Chemother., September 1, 2001; 45(9): 2460 - 2467. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. P. Howden and M. J. Richards The efficacy of continuous infusion flucloxacillin in home therapy for serious staphylococcal infections and cellulitis J. Antimicrob. Chemother., August 1, 2001; 48(2): 311 - 314. [Abstract] [Full Text] [PDF]
|
|